Olema Pharmaceuticals (OLMA) Enterprise Value (2020 - 2026)

Olema Pharmaceuticals (OLMA) has reported Enterprise Value for 7 consecutive years, with -$505.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 28.68% year-over-year to -$505.3 million; the TTM figure through Mar 2026 stood at -$505.3 million (down 28.68% YoY), while the FY2025 annual figure was -$505.4 million, down 16.44% from the prior year.
• Enterprise Value steadied at -$505.3 million in Q1 2026 per OLMA's latest filing, from -$505.4 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$167.4 million in Q2 2023 and bottomed at -$505.4 million in Q4 2025.
• Historically, Enterprise Value has averaged -$297.6 million across 5 years, with a median of -$261.8 million in 2023.
• Annual changes were most pronounced in 2023 — Enterprise Value surged 30.58% — and 2024, when it tumbled 65.8%.
• Olema Pharmaceuticals' Enterprise Value stood at -$204.4 million in 2022, then declined by 28.07% to -$261.8 million in 2023, then sank by 65.8% to -$434.1 million in 2024, then declined by 16.44% to -$505.4 million in 2025, then gained by 0.02% to -$505.3 million in 2026.
• Business Quant data shows OLMA's Enterprise Value at -$505.3 million in Q1 2026, -$505.4 million in Q4 2025, and -$329.0 million in Q3 2025.